Trial closes gap between Bayer’s Nubeqa and rivals in prostate cancer

Bayer’s Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track to expand the eligible patient population for the drug thanks to new phase 3 data.